Literature DB >> 19459712

Understanding and communicating key concepts in risk management: what do we mean by benefit and risk?

I Ralph Edwards, Marie Lindquist.   

Abstract

Mesh：

Year:  2009        PMID： 19459712     DOI： 10.2165/00002018-200932060-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  4 in total

Review 1.  Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?

Authors:  C Bombardier; A Maetzel
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions.

Authors:  Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  The need for definitions in pharmacovigilance.

Authors:  Marie Lindquist
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  A review and critique of assessment instruments for patients with persistent pain.

Authors:  Karen Grimmer-Somers; Nic Vipond; Saravana Kumar; Gillian Hall
Journal:  J Pain Res       Date:  2009-03-11       Impact factor: 3.133
  4 in total
  1 in total

1.  Focusing on risk communication about medicines: why now?

Authors:  Priya Bahri; Mira Harrison-Woolrych
Journal:  Drug Saf       Date:  2012-11-01       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.